TickerFacts.

Viatris Inc (VTRS): R&D Expense

Annual figures by period end, from SEC filings.

$965.90M
Year ended 2025-12-31
+13.4%
3-year compound annual growth
+13.5%
5-year compound annual growth
2020-12-31: $512.60M2021-12-31: $681.00M2022-12-31: $662.20M2023-12-31: $805.20M2024-12-31: $808.70M2025-12-31: $965.90M$965.90M
2020-12-31 R&D Expense (USD) 2025-12-31
Period endedR&D ExpenseChange YoYSource filing
2025-12-31$965.90M+19.4%2026-02-26, From 2025-01-01
2024-12-31$808.70M+0.4%2026-02-26, From 2024-01-01
2023-12-31$805.20M+21.6%2026-02-26, From 2023-01-01
2022-12-31$662.20M-2.8%2025-02-27, From 2022-01-01
2021-12-31$681.00M+32.9%2024-02-28, From 2021-01-01
2020-12-31$512.60Mn/a2023-02-27, From 2020-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
Viatris Inc (VTRS)2025-12-31$965.90M+19.4%
Regeneron Pharmaceuticals, Inc. (REGN)2025-12-31$5.85B+14.0%
Vertex Pharmaceuticals Inc (VRTX)2025-12-31$3.91B+7.7%
Teva Pharmaceutical Industries Ltd (TEVA)2025-12-31$1.01B+1.5%
Bausch Health Companies Inc. (BHC)2025-12-31$629.00M+2.1%
Zoetis Inc. (ZTS)2025-12-31$698.00M+1.7%
Organon & Co. (OGN)2025-12-31$366.00M-22.0%
BeOne Medicines Ltd. (ONC)2025-12-31$2.15B+9.9%
Elanco Animal Health Inc (ELAN)2025-12-31$368.00M+7.0%

Compare VTRS, REGN, VRTX, TEVA side by side · Screen every company in Pharmaceutical Preparations ↗